一份最新的行业分析报告揭示了全球及中国高效液相色谱（HPLC）市场的运作状况及前景动态，时间跨度从 2025年至2031年。该报告由中智信投研究网发布，详细探讨了美国关税政策对HPLC产业的深远影响，以及这一 市场在未来几年的发展趋势。 报告首先定义了HPLC产品，并深入解析了美国关税政策的核心内容。研究指出，关税政策的调整不仅影响了全 球供应链，还迫使中国HPLC企业加快国际化步伐，以应对国内市场的饱和和全球化的机遇。报告设定了明确的 研究目标和方法，旨在分析政策影响，并为企业提出应对策略和未来规划建议。 在行业影响评估部分，报告预测了未来几年全球HPLC行业的规模趋势，并分别考虑了乐观、保守和悲观三种情 形。报告还详细分析了关税政策对中国HPLC企业的直接影响，包括成本上升、市场准入压力增加以及供应链重 构的挑战。 报告进一步分析了全球HPLC市场的企业市场占有率，提供了近三年主要企业的收入、销量及价格数据。数据显 示，全球HPLC市场集中度较高，少数领先企业占据了大部分市场份额。报告还列举了全球主要厂商的高效液相 色谱产品规格、参数及应用领域，并分析了行业的竞争程度。 报告还展望了全球HPLC产业的未来 ...

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Waters Corporation (NYSE: WAT) related to its merger with BD and Company’s Biosciences and Diagnostic Solutions. Upon completion of ...

Core Insights - Becton, Dickinson and Company (BDX) and Waters Corporation (WAT) have announced a strategic collaboration to merge BD's Biosciences Diagnostic Solutions business with Waters' analytical technologies expertise, creating a new entity focused on high-throughput testing in life sciences and diagnostics [1][9] Transaction Details - The merger has been unanimously approved by both companies' boards and is expected to close by the end of Q1 2026, pending regulatory and shareholder approvals [2] - BD will receive $4 billion in cash and hold a 39.2% stake in the new entity through a Reverse Morris Trust structure [8][12] Financial Projections - The combined company aims for $6.5 billion in revenues by 2025, with projections of reaching $9 billion and $3.3 billion in EBITDA by 2030 [8][11] - The total addressable market is expected to double to approximately $40 billion, allowing access to adjacent segments [10] Synergy and Growth Potential - The merger is projected to generate approximately $200 million in cost synergies by the third year post-closing and $290 million in revenue synergies by the fifth year [13] - Annualized EBITDA gains of about $345 million are anticipated by 2030, reinforcing the long-term value creation potential of the transaction [13] Market Position and Performance - BD currently has a market capitalization of $50.76 billion and an earnings yield of 8.1%, outperforming the industry average of 5.3% [5] - BDX shares have lost 21.9% year-to-date, contrasting with a 6.1% gain in the S&P 500 during the same period [3]

Core Viewpoint - The merger between BD and Waters aims to create a new leader in the life sciences and diagnostics sector, targeting the expanding precision medicine and biopharmaceutical markets with a total transaction value of approximately $17.5 billion [1][4][17]. Recent Developments and Future Outlook - In February 2025, BD announced plans to divest its biosciences and diagnostics business, followed by the merger agreement with Waters on July 14, 2025, with completion expected by the end of Q1 2026, pending regulatory approval [3]. - The global life sciences instrument market is projected to reach $85 billion by 2030, with a CAGR of approximately 5-6%, highlighting significant growth opportunities in precision medicine, biopharmaceuticals, and multiplex diagnostics [3]. Strategic Motives - The transaction reflects a strategic shift for both companies: BD focuses on core medical technologies, while Waters seeks to transform its business model from single instrument sales to recurring revenue in diagnostics and services [4][5]. - BD's divestiture aligns with its strategy to concentrate resources on core products like syringes and smart medical devices, which are closely tied to hospital workflows [4][7]. Industry Landscape and Market Opportunities - The merger occurs in a competitive environment where major players like Thermo Fisher and Danaher have expanded through acquisitions, creating pressure on mid-sized analytical instrument companies [5]. - The new company is expected to leverage BD's established presence in Asia, particularly in China and Japan, to enhance global expansion potential [3]. Technical Complementarity - The merger is significant for its technical complementarity, enabling a full chain capability from molecular analysis to cellular detection, which is crucial for biopharmaceutical development and personalized medicine [9][10]. Synergies and Collaborative Value - BD and Waters anticipate achieving approximately $200 million in cost synergies and $290 million in revenue synergies post-merger, but the focus is on the broader industry collaborative value rather than just financial metrics [11]. - The integration of technologies and market strategies is expected to enhance their competitive edge in the life sciences sector [12][16]. Product and Service Integration - The combined entity will offer a comprehensive solution that integrates molecular diagnostics and analytical capabilities, addressing the full spectrum of biopharmaceutical research and clinical validation needs [15]. - The merger allows for the development of complex multiplex testing products, enhancing diagnostic speed and accuracy [15]. Conclusion - The merger between BD and Waters represents a transformative move in the life sciences and diagnostics industry, positioning the new company as a key player in advancing precision medicine and biopharmaceutical innovation [17].

Core Viewpoint - The merger between Waters and BD, valued at $17.5 billion, is driven by strategic alignment, technological complementarity, attractive financial terms, and manageable antitrust risks [1][2]. Strategic Alignment - BD's divestiture of its life sciences business aims to focus on medical technology, aligning with Waters' position as a pure scientific instrument company [3]. - The non-competitive nature of their businesses mitigates overlap risks, as Waters' technologies are distinct from BD's offerings [3]. - BD's use of a reverse Morris Trust structure allows it to retain 39.2% equity in the merged entity while receiving $4 billion in cash for shareholder value maximization [3]. Technological Complementarity - The combination of Waters and BD's technologies creates a comprehensive solution from bioanalysis to clinical testing, addressing core needs in life sciences and diagnostics [4]. - Waters' ACQUITY UPLC and Xevo mass spectrometry platforms are recognized as gold standards for biopharmaceutical quality control, while BD's flow cytometry and molecular diagnostics focus on rapid clinical sample testing [4][5]. Market Synergy - The total addressable market (TAM) is expected to double from $19 billion to $40 billion, covering high-growth areas such as biopharmaceuticals and microbiological diagnostics [6]. - The merger allows for cross-selling opportunities, leveraging Waters' pharmaceutical clients and BD's deep penetration in hospital laboratories [6]. Financial Strength and Integration Capability - Waters' financial structure remains robust, with a net debt to EBITDA ratio of 2.3, significantly below the industry average [7]. - The integration plan emphasizes technology complementarity over scale, with a focus on retaining key production and R&D capabilities [8]. Antitrust Risk Management - The merger faces minimal regulatory resistance due to Waters' lower market share in the flow cytometry space compared to competitors [9]. - The reverse Morris Trust structure offers unique tax advantages for BD shareholders, making it more appealing than cash offers from other bidders [10]. Industry Trends and Growth Potential - The rise of biopharmaceuticals and precision medicine is driving demand for high-sensitivity analytical tools, which both companies can fulfill through their combined technologies [11][12]. - Automation and digitalization capabilities will enhance operational efficiency, providing comprehensive solutions that integrate hardware, software, and services [13]. - The merger not only fills Waters' gaps in clinical diagnostics but also creates maximum value for BD shareholders through strategic design and synergy [14].

Mergers and Acquisitions - Monogram Technologies Inc. will be acquired by Zimmer Biomet Holdings, Inc. for $4.04 per share, totaling an equity value of approximately $177 million and an enterprise value of about $168 million. Shareholders may also receive a contingent value right worth up to $12.37 per share if certain milestones are met by 2030 [2] - Veritex Holdings, Inc. is set to be acquired by Huntington Bancshares Incorporated in a stock transaction where HBI will issue 1.95 shares for each Veritex share, implying a value of $33.91 per share and an aggregate transaction value of $1.9 billion [4] - ESSA Pharma Inc. will be acquired by XenoTherapeutics, Inc. for approximately $1.91 in cash per share, along with a contingent value right that could yield up to $0.06 per share within 18 months post-transaction [6] - Waters Corporation will merge with Becton, Dickinson and Company, with BD's shareholders expected to own about 39.2% and Waters' shareholders approximately 60.8% of the combined entity [8] Investigations - Investigations are ongoing regarding whether the boards of Monogram, Veritex, ESSA, and Waters breached their fiduciary duties by failing to conduct fair processes in their respective transactions and whether the deal considerations provide fair value to shareholders [2][4][6][8]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Group 1 - The core viewpoint of the article highlights the strategic acquisition of Becton, Dickinson & Company by Waters Corporation, aiming to create a leader in the life sciences and diagnostics sector through a deal valued at approximately $17.5 billion [1][3]. Group 2 - The transaction will be executed using a Reverse Morris Trust structure, which is a tax-efficient method for mergers and acquisitions [1]. - The integration of Becton Dickinson's biosciences and diagnostic solutions business is expected to enhance Waters Corporation's capabilities in the life sciences market [1].

Summary of Waters Corporation and BD Biosciences and Diagnostic Solutions Conference Call Company and Industry Overview - **Companies Involved**: Waters Corporation (WAT) and BD Biosciences and Diagnostic Solutions - **Industry**: Life Sciences and Diagnostics Key Points and Arguments 1. **M&A Announcement**: Waters announced a combination with BD's Biosciences and Diagnostic Solutions via a Reverse Morris Trust, issuing 39.2% of its shares to BD shareholders and assuming $4 billion in debt [2][5][43] 2. **Financial Projections**: The combined company is expected to generate pro forma revenue of approximately $6.5 billion with adjusted EBITDA of around $2 billion for 2025 [6][18] 3. **R&D Investment**: Approximately 10% of product sales will be allocated to R&D to sustain innovation [7][16] 4. **Employee Count and Headquarters**: The combined entity will have around 16,000 employees and will be headquartered in Milford, Massachusetts [7] 5. **Market Expansion**: The transaction is expected to double Waters' total addressable market to approximately $40 billion, with growth driven by consistent demand factors such as pill count and disease detection [8][11] 6. **Revenue Stability**: Over 70% of the combined revenue is expected to be recurring, enhancing growth stability [9][10] 7. **Cost and Revenue Synergies**: Expected cost synergies of $200 million by year three and revenue synergies of $290 million by year five [19][40] 8. **Adjusted Operating Margin**: The combined company aims to expand its adjusted operating margin by approximately 500 basis points by 2030 [18][42] Additional Important Insights 1. **Strategic Fit**: The combination is seen as a unique opportunity to leverage complementary capabilities in regulated high-volume applications, enhancing the growth profile of both companies [12][14] 2. **Innovation Pipeline**: BD's expertise in flow cytometry and microbiology complements Waters' strengths in liquid chromatography, creating opportunities for cross-selling and new product development [23][25][30] 3. **Customer Base**: The merger is expected to enhance customer trust and loyalty, with over 80% of the combined company's revenue coming from iconic brands [16][61] 4. **Market Positioning**: BD's strong presence in diagnostics and microbiology is expected to accelerate Waters' entry into high-growth adjacencies such as bioseparations and bioanalytical characterization [35][37] 5. **Regulatory and Market Access**: The combination will provide Waters with the necessary regulatory and market access capabilities to enhance its diagnostics offerings [76][88] Conclusion The merger between Waters Corporation and BD Biosciences and Diagnostic Solutions is positioned as a transformative move that will create a leader in the life sciences and diagnostics industry, with significant potential for innovation, market expansion, and financial growth. The strategic alignment of both companies' strengths is expected to deliver substantial long-term value to shareholders and customers alike [46][47].

Summary of Becton, Dickinson and Company (BDX) and Waters Corporation Conference Call Industry and Companies Involved - **Industry**: Life Sciences and Diagnostics - **Companies**: Waters Corporation and Becton, Dickinson and Company (BDX) Core Points and Arguments 1. **M&A Announcement**: Waters announced a combination with BD's Biosciences and Diagnostic Solutions business via a Reverse Morris Trust, with Waters issuing 39.2% of its shares to BD shareholders and assuming $4 billion in debt [3][6][44]. 2. **Financial Projections**: The combined company is expected to generate pro forma revenue of approximately $6.5 billion and adjusted EBITDA of around $2 billion for 2025 [7][19]. 3. **R&D Investment**: Approximately 10% of product sales will be allocated to R&D to sustain innovation [8][17]. 4. **Employee Count and Headquarters**: The combined entity will have around 16,000 employees and will be headquartered in Milford, Massachusetts [8]. 5. **Market Expansion**: The transaction is expected to double Waters' total addressable market to approximately $40 billion, with a focus on high-volume, regulated applications [9][12]. 6. **Revenue Stability**: Over 70% of the combined revenue is expected to be recurring, enhancing growth stability [10][11]. 7. **Cost and Revenue Synergies**: Expected cost synergies of $200 million by year three and revenue synergies of $290 million by year five [20][41]. 8. **Adjusted Operating Margin**: The combined company aims for an adjusted operating margin of approximately 32% by 2030, with an initial margin of 27% [19][43]. 9. **Strategic Fit**: The combination enhances capabilities in bioseparations, bioanalytical characterization, and multiplex diagnostics, leveraging both companies' strengths [15][36][38]. 10. **Customer Base**: The merger allows for cross-selling opportunities, particularly in flow cytometry and diagnostics, enhancing customer access and service offerings [56][91]. Additional Important Content 1. **Historical Growth**: Both companies have historically grown at mid-single-digit rates, with BD's bioscience and diagnostic solutions business having approximately 80% annual recurring revenue [18][19]. 2. **Innovation Pipeline**: BD's Biosciences is noted for its strong innovation pipeline in flow cytometry and microbiology, while Waters has a robust portfolio in chemistry and analytics [24][26][30]. 3. **Market Positioning**: The combined company is positioned to lead in life sciences tools, with a focus on regulated high-volume settings [47][48]. 4. **Regulatory and Market Access**: The merger is expected to enhance regulatory capabilities and market access for diagnostics, particularly in high-throughput labs [78][92]. 5. **Long-term Value Creation**: The transaction is described as transformational, aiming to create significant long-term value for shareholders, customers, and employees [47][48]. This summary encapsulates the key points from the conference call regarding the merger between Waters Corporation and BD's Biosciences and Diagnostic Solutions, highlighting the strategic, operational, and financial implications of the transaction.